More insights in sight: Comprehensive genomic profiling with SureSelect Cancer CGP Assay

In this product brochure, Agilent Technologies presents the SureSelect Cancer CGP Assay. The SureSelect Cancer CGP assay offers comprehensive genomic profiling for solid tumors. This pan-cancer NGS panel enables detection of somatic variants, including single nucleotide variants (SNVs), copy number variants (CNVs), insertions/deletions (indels), translocations (TLs), gene fusions, and the immuno-oncology biomarkers TMB (tumor mutational burden) and MSI (microsatellite instability). Powered by SureSelect XT HS2 library preparation and target enrichment chemistry, the assay features fast hybridization, low sample input, enzymatic fragmentation, and a one-day workflow to generate NGS sequencing-ready libraries. Automation options reduce hands-on time to maximize lab efficiency.